Cargando…

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study

BACKGROUND: There is inconsistency in the criteria used to define anti-vascular endothelial growth factor (VEGF) drug-induced hypertension (AVEGF-HT) in published studies. It is unknown whether specific patient characteristics similarly predict AVEGF-HT using different criteria. METHODS: We assessed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mangoni, Arduino A., Kichenadasse, Ganessan, Rowland, Andrew, Sorich, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802603/ https://www.ncbi.nlm.nih.gov/pubmed/29434680 http://dx.doi.org/10.1177/1758834018755090

Ejemplares similares

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data
por: Sorich, Michael J, et al.
Publicado: (2016)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil
por: Rowland, Angela, et al.
Publicado: (2016)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
por: Hopkins, Ashley M, et al.
Publicado: (2023)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Targeted pharmacotherapy after somatic cancer mutation screening
por: Polasek, Thomas M., et al.
Publicado: (2016)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
por: Hopkins, Ashley M, et al.
Publicado: (2017)

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
por: Sternberg, Cora N., et al.
Publicado: (2019)

Nuances to precision dosing strategies of targeted cancer medicines
por: Hopkins, Ashley M., et al.
Publicado: (2020)

The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data
por: Modi, Natansh D., et al.
Publicado: (2020)

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges
por: van Leuven, Jason, et al.
Publicado: (2023)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Modi, Natansh D., et al.
Publicado: (2021)

Validation and Adaptation of the Multidimensional Prognostic Index in an Older Australian Cohort
por: Bryant, Kimberley, et al.
Publicado: (2019)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Use of Multiprognostic Index Domain Scores, Clinical Data, and Machine Learning to Improve 12-Month Mortality Risk Prediction in Older Hospitalized Patients: Prospective Cohort Study
por: Woodman, Richard John, et al.
Publicado: (2021)

Placental Malaria: Hypertension, VEGF, and Prolactin
por: Pearson, Roy Douglas
Publicado: (2007)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
por: Guo, Jun, et al.
Publicado: (2018)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
por: Sheng, Xinan, et al.
Publicado: (2020)

Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages
por: Hopkins, Ashley M., et al.
Publicado: (2023)

Radiation Induced Leiomyosarcoma Three Decades After Treatment for Wilms’ Tumor
por: Khattak, Muhammad A, et al.
Publicado: (2010)

Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report
por: Abbas, M. Nazim, et al.
Publicado: (2021)

Non-steroidal anti-inflammatory drug (NSAID) related inhibition of aldosterone glucuronidation and arterial dysfunction in patients with rheumatoid arthritis: a cross-sectional clinical study
por: Crilly, Michael A, et al.
Publicado: (2011)

Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors
por: Touyz, Rhian M., et al.
Publicado: (2019)

Acute Hypertensive Retinochoroidopathy Secondary to an Anti-cancer Drug (apatinib): The First Case Report
por: Yao, Bangtao, et al.
Publicado: (2021)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Anti-Hypertensive Drugs Have Different Effects on Ventricular Hypertrophy Regression
por: Filho, Celso Ferreira, et al.
Publicado: (2010)

Bilateral Hypertensive Retinopathy Complicated with Retinal Neovascularization: Panretinal Photocoagulation or Intravitreal Anti-VEGF Treatment?
por: Georgiadis, Odysseas, et al.
Publicado: (2014)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
por: Stewart, Michael W
Publicado: (2012)

Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered
por: Hanhart, Joel, et al.
Publicado: (2023)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
por: Hopkins, Ashley M., et al.
Publicado: (2019)

A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies
por: Modi, Natansh D., et al.
Publicado: (2023)

Prognostic Value of Masked Uncontrolled Hypertension Defined by Different Ambulatory Blood Pressure Criteria
por: Coccina, Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3rou7lgcbmos9ms09bj3kr0h50